ANALYST RATINGS

RBC Capital Reiterates Vertiv Stock Rating

RBC Capital reaffirms Vertiv's Outperform rating and $435 target, citing strong datacenter growth and ambitious 2030 goals.

ByMia Lopez- Senior Editor

Today / 13:44|Last updated: Today / 13:47

0

0

RBC Capital Reiterates Vertiv Stock Rating — Photo: Prepared by Bond.az

RBC Capital has reiterated an Outperform rating and $435 price target for Vertiv Holdings Co. (NYSE:VRT) after the company's investor day.

Vertiv set new five-year targets, including 20-22% organic revenue CAGR through 2030, above consensus estimates. The company also targets EPS above $17 by 2030.

The analyst cited North America's 12-year datacenter construction backlog as a growth catalyst. Vertiv's investments in prefabricated power platforms, 800VDC technology, and services were highlighted.

More News

KeyBanc cuts Lowe's target to $275

Today / 13:52

|

226

KeyBanc cuts Lowe's target to $275

KeyBanc cuts Lowe's price target to $275 from $300 but maintains Overweight rating due to market share gains.

ANALYST RATINGS →

0

0

KeyBanc cuts Autodesk price target to $341

Today / 13:50

|

515

KeyBanc cuts Autodesk price target to $341

KeyBanc lowers Autodesk price target to $341 from $365, keeping Overweight rating. Stock at $235.11. Bond.az reports.

ANALYST RATINGS →

0

0

Nouveau Monde Graphite Price Target Cut to $4.50

Today / 11:34

|

389

Nouveau Monde Graphite Price Target Cut to $4.50

H.C. Wainwright cuts Nouveau Monde Graphite price target to $4.50. Stock trades at $1.97 as Matawinie mine construction begins.

ANALYST RATINGS →

0

0

Cantor Fitzgerald Reaffirms Nvidia Overweight Rating

Today / 11:33

|

796

Cantor Fitzgerald Reaffirms Nvidia Overweight Rating

Cantor Fitzgerald reaffirms Nvidia Overweight rating, $350 target. Strong data center growth drives performance.

ANALYST RATINGS →

0

0

Belite Bio Stock Rises on NDA Progress

Today / 11:32

|

645

Belite Bio Stock Rises on NDA Progress

Belite Bio stock rises as H.C. Wainwright reiterates Buy rating and NDA progresses. Tinlarebant potential FDA approval expected in Q1 2027.

ANALYST RATINGS →

0

0

H.C. Wainwright Raises Immunovant Target to $40

Today / 11:31

|

420

H.C. Wainwright Raises Immunovant Target to $40

H.C. Wainwright raises Immunovant price target to $40 from $35 after positive Phase 2 RA data, maintains Buy rating.

ANALYST RATINGS →

0

0

Applied Digital Price Target Raised to $66

Today / 11:21

|

614

Applied Digital Price Target Raised to $66

Needham raises Applied Digital price target to $66 after a major 300MW lease agreement. Strong growth outlook.

ANALYST RATINGS →

0

0

Wolfe Research Cuts Lowe's Price Target on Weak Demand

Today / 11:00

|

299

Wolfe Research Cuts Lowe's Price Target on Weak Demand

Wolfe Research lowers Lowe's price target to $254 on muted demand outlook, maintaining Outperform rating.

ANALYST RATINGS →

0

0

UBS Upgrades Sumco Stock Rating

Today / 09:21

|

578

UBS Upgrades Sumco Stock Rating

UBS upgraded Sumco Corp to Neutral with a new price target of JPY 3,100. Get the latest Sumco stock news on Bond.az.

ANALYST RATINGS →

0

0

Barclays Reiterates Overweight on Nvidia with $275 Target

Today / 09:20

|

523

Barclays Reiterates Overweight on Nvidia with $275 Target

Barclays reiterates Overweight rating on Nvidia stock with a $275 price target after strong quarterly results and raised guidance.

ANALYST RATINGS →

0

0

Raymond James Downgrades NOG Stock Rating

Today / 08:42

|

674

Raymond James Downgrades NOG Stock Rating

Raymond James downgrades NOG from Strong Buy to Outperform. Price target lowered to $35.

ANALYST RATINGS →

0

0

Jefferies downgrades ZoomInfo stock on AI

Today / 08:14

|

515

Jefferies downgrades ZoomInfo stock on AI

Jefferies downgrades ZoomInfo to Hold, cuts price target to $4.00 on weak demand and AI adoption headwinds.

ANALYST RATINGS →

0

0

...